Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

This study aims to explore the recommended phase 2 dose and evaluate the safety, tolerability and preliminary antitumor activity of BGB-16673 monotherapy at the recommended Phase 2 dose for the selected B-cell malignancy expansion cohorts

Participants needed: 146
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: BeiGeneUpdated: Aug 21, 2026Locations: 29
Eligibility criteria

Provision of signed and dated written informed consent prior to any study [+5]

Prior malignancy (other than the disease under study) within the past 2 years, e... [+4]

Read more
Status: Recruiting

Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia

This is a hybrid (retrospective and prospective) non-interventional registry study to further describe the clinical profile of zanubrutinib in Waldenström macroglobulinemia (WM) participants with and without specific mutations and from racial and ethnic minority groups. Data collected from this registry study will be used to better understand the clinical benefit and safety of zanubrutinib for the treatment of participants in these populations.

Participants needed: 111
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: BeiGeneUpdated: Aug 7, 2026Locations: 8Duration: 5 Years
Eligibility criteria

Clinical and definitive histologic diagnosis of WM [+4]

Evidence of disease transformation before the first dose of zanubrutinib [+3]

Read more
Status: Recruiting

Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

In this Phase 2, Single-Arm, Multi-Center, Open-Label Study, participants with previously treated locally advanced unresectable or metastatic solid tumors with mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) will be treated with anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317).

Participants needed: 200
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: BeiGeneUpdated: Jul 10, 2026Locations: 30
Eligibility criteria

Having histological confirmed diagnosis of malignancy [+5]

Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2 or any other antibody or... [+12]

Read more